NLS Pharmaceutics Teams Up with Kadimastem and TargetGene for Collaboration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Should l Buy ?
Collaboration Announcement: NLS Pharmaceutics and Kadimastem have signed a Memorandum of Understanding with TargetGene Biotechnologies to combine their expertise in cell therapy and gene-editing technologies.
Joint Development Goals: The collaboration aims to develop and optimize gene-edited cell therapy products, focusing on specific genome modifications with minimal off-target effects.
Future Company Structure: The partnership will continue under the new entity, NewCelX, following the anticipated merger between NLS and Kadimastem.
Framework for Innovation: The MOU establishes a framework for joint research and development activities, technology exchange, and potential licensing opportunities between the companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
